Arcutis Biotherapeutics, Inc.: Psoriasis trials

The registry lists 10 Psoriasis studies with Arcutis Biotherapeutics, Inc. as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 1 3Phase 2 6Phase 3 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)CompletedNCT04746911Phase 2Results posted
• Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)CompletedNCT04655313Phase 2Results posted
• Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque PsoriasisCompletedNCT04211389Phase 3Results posted
• Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque PsoriasisCompletedNCT04211363Phase 3Results posted
• Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body PsoriasisCompletedNCT04128007Phase 2Results posted
• Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque PsoriasisCompletedNCT03764475Phase 2Results posted
• The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque PsoriasisCompletedNCT03638258Phase 2Results posted
• Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque PsoriasisCompletedNCT03392168Phase 1/2Results posted
• Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body PsoriasisCompletedNCT07340216Phase 1
• Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque PsoriasisCompletedNCT04279119Phase 1